Open-Label Extension Study to Assess GLM101 in PMM2-CDG Patients | MicrobiomeTrials← Back to trialsNCT06657859
Open-Label Extension Study to Assess GLM101 in PMM2-CDG Patients
ENROLLING_BY_INVITATIONPHASE2INTERVENTIONAL
Trial Details
Start: 2024-09-30Est. Completion: 2029-09
Enrollment target: 90 participants Locations- University of Minnesota, Minneapolis, Minnesota, United States
- The Icahn School of Medicine at Mount Sinai, New York, New York, United States
- The Children's Hospital of Philadelphia (CHOP), Philadelphia, Pennsylvania, United States
- Seattle Children's Hospital, Seattle, Washington, United States
- Vseobecna fakultni nemocnice v Praze, Prague, Czechia
- AP-HP Hopital Universitaire Necker-Enfants Malades, Paris, France
- Universitaetsklinikum Münster, Münster, Germany
- Azienda Ospedaliero Universitaria Policlinico G. Rodolico-San Marco - Presidio Ospedaliero G. Rodolico, Catania, Italy
- Azienda Ospedaliero Universitaria Pisana, Pisa, Italy
- Unidade Local de Saúde de Santo António, E.P.E, Porto, Portugal
- Hospital Sant Joan de Déu, Esplugues de Llobregat, Spain
- Hospital Universitario 12 de Octubre - Unidad Pediatrica de Investigacion y Ensayos Clinicos (UPIC), Madrid, Spain
- Hospital Universitario 12 de Octubre, Madrid, Spain
- Birmingham Children's Hospital, Birmingham, United Kingdom
- Great Ormond Street Hospital for Children, London, United Kingdom
Other microbiome trials you might be interested in
Congenital Disorders of Glycosylation
The purpose of this research is to study the natural history of congenital disorders of glycosylation and its causes and…
San Diego, United StatesEst. completion Jul 31, 2030
Phosphomannomutase 2 Deficiency
Clinical and Basic Investigations into Phosphomannomutase deficiency (PMM2-CDG)
This is a natural history (observationa…
Rochester, United StatesCompleted Apr 9, 2026